Cancer Genetics, Inc. Sustainability Profile
Cancer Genetics, Inc., a leading player in the oncology-focused genetic testing industry, is headquartered in the United States. Founded in 2000, the company has established itself as a pioneer in providing advanced genomic testing services that aid in the diagnosis and management of cancer. With a strong presence across major operational regions in North America and Europe, Cancer Genetics, Inc. offers a comprehensive suite of products, including molecular diagnostics and genomic profiling. What sets Cancer Genetics apart is its commitment to precision medicine, utilising cutting-edge technology to deliver tailored insights for oncologists and patients alike. The company has achieved significant milestones, including partnerships with prominent healthcare institutions, solidifying its market position as a trusted provider of cancer-related genetic information. Through its innovative approach, Cancer Genetics, Inc. continues to make strides in improving patient outcomes in the fight against cancer.
DitchCarbon Score
How does Cancer Genetics, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Business Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Cancer Genetics, Inc.'s score of 25 is lower than 62% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Cancer Genetics, Inc.'s reported carbon emissions
In 2022, Cancer Genetics, Inc. reported total carbon emissions of approximately 686,600 kg CO2e, comprising 404,000 kg CO2e from Scope 1 emissions and 282,600 kg CO2e from Scope 2 emissions. This data reflects a significant reduction from 2021, where Scope 1 emissions alone were reported at 533,000,000 kg CO2e. Despite these figures, Cancer Genetics, Inc. has not disclosed any Scope 3 emissions data, nor have they set specific reduction targets or initiatives as part of their climate commitments. The emissions data is cascaded from the parent company, indicating a merged entity relationship, but no specific climate pledges or initiatives have been identified. Overall, while Cancer Genetics, Inc. has made strides in reducing their emissions, further transparency regarding their climate commitments and future reduction targets would enhance their sustainability profile.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2021 | 2022 | |
|---|---|---|
| Scope 1 | 533,000,000 | 000,000 |
| Scope 2 | - | 000,000 |
| Scope 3 | - | - |
How Carbon Intensive is Cancer Genetics, Inc.'s Industry?
How Carbon Intensive is Cancer Genetics, Inc.'s Location?
Cancer Genetics, Inc.'s Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Cancer Genetics, Inc. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
